CHARLOTTESVILLE, Va., Oct. 25 /PRNewswire/ -- Adenosine Therapeutics, LLC, a leading adenosine drug discovery and development company, announced today it has initiated a two-part Phase Ib study in humans to evaluate apadenoson (ATL146e), a potent selective adenosine A2A agonist, as an anti-inflammatory agent.
